High-dose IL-2 appears to benefit some patients with metastatic renal cell carcinoma by producing durable CRs or PRs. Despite severe acute treatment-associated toxicities, IL-2 should be considered for initial therapy of patients with appropriately selected metastatic renal cell carcinoma.
No takes yet. Share an insight, caveat, or question.
Fyfe et al. (1995) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: